Allergan Reports the Acceptance of EMA’s MAA for Abicipar to Treat Neovascular Age-Related Macular Degeneration

 Allergan Reports the Acceptance of EMA’s MAA for Abicipar to Treat Neovascular Age-Related Macular Degeneration

Shots:

  • Molecular Partners announces that EMA has validated the MAA of its partner Allergan for Abicipar to treat patients with nAMD
  • Post-approval, Abicipar will be the first anti-VEGF therapy to maintain vision gains with a 12-week dosing interval. The companies collaborated to advance clinical programs in ophthalmology and to robust pipeline of DARPin drug candidates in oncology and immuno-oncology
  • Abicipar pegol is an anti-VEGF therapy based on the Molecular Partners’ DARPin platform and currently being evaluated in P-III study. Additionally, Molecular Partners has terminated its agreement with Amgen for exclusive development & commercialization of MP0310 which is expected to enter into the clinic in H2’19

Click here to­ read full press release/ article | Ref: Molecular Partners | Image: Stat News